Study on mismatch repair genes of chronic myeloid leukemia.
- Author:
Jun LUO
1
;
Zhi-gang PENG
;
Yan CHEN
;
Yong-rong LAI
;
Yu-ying LU
;
Shan-jun SONG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Agents; pharmacology; Benzamides; DNA Mismatch Repair; Female; Fusion Proteins, bcr-abl; genetics; metabolism; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; genetics; Male; Middle Aged; Piperazines; pharmacology; Pyrimidines; pharmacology; RNA, Messenger; genetics; Reverse Transcriptase Polymerase Chain Reaction
- From: Chinese Journal of Hematology 2006;27(2):103-106
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the expression and regulation mechanism of mismatch repair (MMR) genes in chronic myeloid leukemia (CML).
METHODSExpression of MMR genes hMSH2, hMSH3, hMSH6, hMLH1 and hPMS2 mRNAs in 62 CML patients and K562 cell line were detected by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR). Expression of bcr-abl mRNA and MMR genes mRNA were detected by RT-PCR in 26 CML patients with allogeneic peripheral blood stem cell transplantation (allo-PBSCT) and 4 CML patients on imatinib treatment. Expression of bcr-abl mRNA was detected by RT-PCR and tyrosine phosphorylation of BCR-ABL fusion protein by Western blot.
RESULTSExpression of hMSH2, hMSH3 and hMLH1 mRNA was significantly lower in CML and K562 cells than in normal control (P < 0.05). In 26 CML with allo-PBSCT and 4 CML patients on imatinib treatment, expressions of hMSH2, hMSH3 and hMLH1 mRNA was enhanced while expression of bcr-abl mRNA decreased. In CML MNC after imatinib treatment and in K562 cells, expression of hMSH2, hMSH3 and hMLH1 mRNA was enhanced while tyrosine phosphorylation of BCR-ABL fusion protein decreased.
CONCLUSIONExpressions of hMSH2, hMSH3 and hMLH1 mRNA were down-regulated by bcr-abl fusion gene.
